The market has climbed 2.4% in the last 7 days and 20% over the past year, with earnings forecast to grow by 17% annually. Though the term 'penny stock' might sound like a relic of past trading days, these investments still present opportunities for growth at lower price points when backed by strong financials. In this article, we explore three penny stocks that combine balance sheet strength with potential for outsized gains, offering investors a chance to uncover hidden value in quality companies.

Here's a peek at a few of the choices from the screener.

Alto Ingredients (ALTO)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Alto Ingredients, Inc. operates in the United States, focusing on the production, distribution, and marketing of specialty alcohols, renewable fuel, and essential ingredients with a market cap of $376.58 million.

Operations: The company's revenue is primarily generated from the Pekin Campus Production at $591.55 million, followed by Marketing and Distribution at $229.35 million, and Western Production at $100.64 million.

Market Cap: $376.58M

Alto Ingredients has recently gained attention by being added to multiple Russell indices, indicating increased visibility among investors. The company reported a net income of US$4.27 million for the first quarter of 2026, marking a turnaround from a previous net loss. Its short-term assets exceed both short and long-term liabilities, reflecting solid financial health. However, the company's Return on Equity is considered low at 11.7%, and its interest coverage ratio is below optimal levels at 1.9 times EBIT, suggesting potential challenges in managing debt obligations despite satisfactory overall debt levels with a net debt to equity ratio of 21.1%.

Microvast Holdings (MVST)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Microvast Holdings, Inc. specializes in designing, developing, and manufacturing battery components and systems for electric commercial vehicles and energy storage systems, with a market cap of approximately $273.59 million.

Operations: The company's revenue is primarily derived from its Batteries / Battery Systems segment, totaling $371.64 million.

Market Cap: $273.59M

Microvast Holdings, Inc. faces significant challenges as a penny stock, including recent legal issues with a class action lawsuit alleging misleading statements about its business operations. Despite reducing its debt to equity ratio from 1291.2% to 66.3% over five years and maintaining sufficient cash runway for over three years due to positive free cash flow, the company remains unprofitable with a negative return on equity of -9.18%. Recent financial results showed declining revenue and gross margins, attributed to regulatory shifts and customer delays, leading to substantial stock price declines amidst high volatility and insider selling concerns.

Rocket Pharmaceuticals (RCKT)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Rocket Pharmaceuticals, Inc. is a late-stage biotechnology company that develops, manufactures, and sells genetic therapies for rare and devastating diseases in the United States, with a market cap of $372.35 million.

Operations: Rocket Pharmaceuticals does not report distinct revenue segments.

Market Cap: $372.35M

Rocket Pharmaceuticals, Inc., a pre-revenue biotech company with a market cap of US$372.35 million, faces challenges typical of penny stocks. Despite being debt-free and having short-term assets exceeding liabilities, the company has less than a year of cash runway based on current free cash flow trends. Recent management changes and significant insider selling may raise concerns among investors. The company's stock was recently dropped from several major growth indexes but added to the Russell Microcap Index, reflecting its volatile position in the market landscape. Forecasts suggest potential revenue growth yet profitability remains elusive in the near term.

Where To Now?

• Click this link to deep-dive into the 338 companies within our US Penny Stocks screener.
• Interested In Other Possibilities? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.